LifeMD, Inc. (NASDAQ: LFMD) announced the launch of Novo Nordisk's Wegovy subscription program, which the company describes as the first GLP-1 subscription offering available through its telehealth platform.

The subscription model provides eligible patients with structured pricing that offers up to $1,200 in annual savings for injectable formulations and $600 for oral therapy, according to the company's statement.

"Our inclusion in the Wegovy subscription program is a natural extension of our established relationship with Novo Nordisk," said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD. "This program deepens the value of our collaboration and adds meaningful financial savings for the patients we serve."

LifeMD's collaboration with Novo Nordisk began in 2025 with NovoCare Pharmacy integration and has expanded to include injectable and oral Wegovy and Ozempic products. The company is listed as a telehealth provider on both NovoCare and Wegovy websites.

Through the program, patients receive virtual visits with LifeMD's affiliated medical group across all 50 states, ongoing clinical oversight, access to diagnostic testing, and simplified billing processes.

LifeMD operates as a virtual primary care provider, offering telemedicine services and specialized treatment across more than 200 conditions through its digital care platform and affiliated medical group.